Proteomics

Dataset Information

0

Overcoming intra-tumoral heterogeneity for biomarker discovery in the High-Grade Serous Ovarian Cancer proteome


ABSTRACT: High-grade serous ovarian cancer (HGSC) has a disproportionate impact on cancer-related mortality in women. There is an urgent need to improve treatment options for HGSC. This includes better selection of patients who will benefit from existing treatments, including HRD targeted therapy, and discovery of new targeted therapeutic options. Reliable tissue-based biomarkers that can guide treatment selection are key to progress in this area. A challenge for their definition is the large volume of disease that is characteristically present at HGSC diagnosis and that can show considerable heterogeneity within and between anatomical sites. In order to address this issue, we carried out a detailed study of the HGSC proteome in eleven individuals by comparing genomic and gene-expression features with multiple independent proteomic results derived from fresh frozen (FF) and formalin fixed paraffin embedded (FFPE) samples from both ovary and a common metastatic site, omentum. Our findings gave emphasis to the influence of sample site of origin on biomarker expression, and revealed opportunities to detect mechanisms shaping the HGSC tumour immune microenvironment from tissue proteomics. The dataset also forms a useful resource to investigate molecular heterogeneity in HGSC.

INSTRUMENT(S): TripleTOF 6600

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Ovarian Serous Carcinoma Cell, Ovarian Epithelial Cell

DISEASE(S): Ovarian Serous Carcinoma

SUBMITTER: Srinivas Srikanth Manda  

LAB HEAD: Rosemary Balleine

PROVIDER: PXD042150 | Pride | 2025-06-13

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
171016_E0006_P02_106_S_M04_1.wiff Wiff
171016_E0006_P02_106_S_M04_1.wiff.scan Wiff
171016_E0006_P02_157_S_M04_1.wiff Wiff
171016_E0006_P02_157_S_M04_1.wiff.scan Wiff
171016_E0006_P02_158_S_M04_1.wiff Wiff
Items per page:
1 - 5 of 2714
altmetric image

Publications


Improved biomarkers of treatment response are needed for patients with high-grade serous ovarian cancer (HGSC). A challenge is substantial anatomical site-to-site variation in expression. We completed data-independent acquisition-mass spectrometry (DIA-MS) analysis of 404 fresh frozen and 78 formalin-fixed, paraffin-embedded HGSC tissue samples from the ovary (adnexal) and a common secondary site (omentum) in 11 patients. This was compared with mutation testing, gene expression, and whole-genome  ...[more]

Similar Datasets

2025-03-26 | PXD045405 | Pride
2021-04-22 | PXD017993 | Pride
2022-04-07 | PXD031485 | Pride
2014-02-13 | E-GEOD-47841 | biostudies-arrayexpress
2020-05-27 | PXD014980 | Pride
2022-02-15 | PXD028044 | Pride
2011-09-14 | E-GEOD-31735 | biostudies-arrayexpress
2025-03-26 | PXD054596 | Pride
2023-03-11 | PXD035084 | Pride
2024-01-29 | PXD034493 | Pride